Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
暂无分享,去创建一个
T. Fehm | H. Brauch | M. Eichelbaum | M. Schwab | W. Schroth | S. Winter | W. Simon | P. Fasching | T. Mürdter | P. Fasching | G. Heinkele | T. Mürdter | L. Bacchus-Gerybadze | T. Fehm | L. Bacchus‐Gerybadze
[1] R. Desnick,et al. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. , 2010, Analytical chemistry.
[2] S. Lundgren,et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer , 2010, BMC Cancer.
[3] R. Weinshilboum,et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Yusuke Nakamura,et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Buzdar,et al. Aromatase inhibitors alone or in sequence with tamoxifen - Clinical Evaluation of the BIG 1-98 trial , 2010, Expert opinion on pharmacotherapy.
[6] K. Lunetta,et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen , 2010, Acta oncologica.
[7] H. Brauch,et al. Pharmacogenomics of tamoxifen therapy. , 2009, Clinical chemistry.
[8] L. Carey,et al. CYP2D6 and tamoxifen: DNA matters in breast cancer , 2009, Nature Reviews Cancer.
[9] S. Amin,et al. Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases , 2007, Drug Metabolism and Disposition.
[10] Hyeong-Seok Lim,et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Pike,et al. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Eichelbaum,et al. TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells , 2007, Breast Cancer Research and Treatment.
[13] Yi-Tong Liu,et al. Drugs as CYP3A Probes, Inducers, and Inhibitors , 2007, Drug metabolism reviews.
[14] R. Dellinger,et al. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants , 2006, Breast Cancer Research.
[15] Zeruesenay Desta,et al. Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells , 2006, Journal of Pharmacology and Experimental Therapeutics.
[16] Zeruesenay Desta,et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.
[17] G. Mellgren,et al. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. , 2005, Journal of chromatography. A.
[18] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[19] David A. Flockhart,et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.
[20] David A. Flockhart,et al. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.
[21] K. Muro,et al. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. , 2004, Biochemical pharmacology.
[22] T. Skaar,et al. Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.
[23] Zeruesenay Desta,et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.
[24] D. Flockhart,et al. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[25] T. Mürdter,et al. Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]-dextrorphan and [2H3]-dextrorphan-β-glucuronide , 2002 .
[26] E. Gillam,et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[27] M. Eichelbaum,et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British journal of clinical pharmacology.
[28] H. Glaeser,et al. Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine* , 2002, The Journal of Biological Chemistry.
[29] J. Guitton,et al. Rapid and simple method to determine tamoxifen and its major metabolites in human liver microsomes by high performance liquid chromatography with fluorescence detection , 1998 .
[30] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[31] G. Tucker,et al. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. , 1997, Biochemical pharmacology.
[32] J. Mailhot,et al. New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction. , 1996, The Journal of organic chemistry.
[33] I. Wainer,et al. Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. , 1994, Journal of chromatography. B, Biomedical applications.
[34] J H Lamb,et al. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. , 1994, Carcinogenesis.
[35] W. McGuire,et al. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] C. Osborne,et al. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.
[37] S. Lundgren,et al. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. , 1989, Cancer research.
[38] P. Ueland,et al. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. , 1988, Cancer research.
[39] M. Namer,et al. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. , 1987, British Journal of Cancer.
[40] V. Jordan,et al. EVIDENCE FOR THE METABOLIC ACTIVATION OF NON‐STEROIDAL ANTIOESTROGENS: A STUDY OF STRUCTURE‐ACTIVITY RELATIONSHIPS , 1980, British journal of pharmacology.
[41] V. Jordan,et al. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.
[42] S. Lundgren,et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] David A. Flockhart,et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.
[44] Ulrich M. Zanger,et al. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[45] E. Gillam,et al. OF TAMOXIFEN BY RECOMBINANT HUMAN CYTOCHROME P 450 ENZYMES : FORMATION OF THE 4-HYDROXY , 4-HYDROXY AND N-DESMETHYL METABOLITES AND ISOMERIZATION OF trans-4-HYDROXYTAMOXIFEN , 2002 .
[46] A. Segre,et al. A study of structure-activity relationships in 4-deoxypyrido[1',2'-1,2]imidazo[5,4-c]rifamycin SV derivatives by electron spectroscopy for chemical analysis and 1H NMR. , 1985, Molecular pharmacology.
[47] B. Katzenellenbogen,et al. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. , 1984, Cancer research.
[48] H. Rochefort,et al. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. , 1982, Cancer research.